STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment
Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?
Erasca, a U.S.-based biotech company, is touting its KRAS-targeted treatment, ERAS-0015, as a potentially more potent and better-tolerated pan-RAS inhibitor compared to Revolution Medicines' Rasonque. The company has backed up this claim with limited data from an early-stage study, but its valuation remains a fraction of Revolution Medicines' $35 billion market value.
Erasca is set to present more data on ERAS-0015 at the EORTC-NCI-AACR “Triple” meeting in Barcelona, with CEO Jonathan Lim signaling a potentially significant response rate in second-line pancreatic cancer.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.